Nucleoside derivatives and therapeutic use thereof
The present invention relates to nucleoside derivatives represented by general formulas I and II, their synthetic methods and their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.
1. A compound of the formula:
wherein:
A is selected from
Y═H or OH and X═H, F, Cl, Br, I, or CH 3 ;
or a pharmaceutically acceptable salt thereof with the proviso that, when A is
X is not CH 3 .
2. The compound of claim 1 having the formula
wherein: Y═H or OH and X═H, F, Cl, Br, I, or CH 3 or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1 , having the formula:
wherein: Y═H or OH and X═H, F, Cl, Br or I or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 that is:
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 having an IC 50 of not greater than 10 μM with respect to at least one cell line for a tumor selected from tumors of the ovary, tumors of the breast, cervical tumors, tumors of the prostate, tumors of the liver, lung tumors, kidney tumors, colon tumors, pancreatic tumors, brain tumors, stomach tumors and melanoma.
6. The compound according to claim 5 , wherein said cell line is selected from Human OVCAR-3 for tumors of the ovary, MCF-7 or MDA-MB-231 for breast tumors, HeLa for cervical tumors, PC3 or LNCap for tumors of the prostate, HepG2 for tumors of the liver, A549 or NCI-H226 for lung tumors, UMRC2 for kidney tumors, HT-29 or HCT116 colon tumors, PANC-1 for pancreatic tumors, U251 for brain tumors, MKN-45 for stomach tumors and SK-MEL-28 for melanoma.
7. The compound of claim 5 , having an IC 50 of not greater than 1.0 μM.
8. The compound of claim 5 , having an IC 50 of not greater than 0.5 μM.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
10. A method of synthesizing a compound of formula:
wherein: Y═H or OH and X═H, F, Cl, Br, I, or CH 3 or a compound of the formula
wherein: Y═H or OH and X═H, F, Cl, Br, or I, comprising at least one step selected from the group:
wherein B is selected from tert-butyldimethyl silyl, tert-butyldiphenyl silyl, and trityl.
11. The method of claim 10 , wherein B is trityl.
12. A method for treating a tumor comprising administering a composition comprising a compound of the formula:
wherein: Y═H or OH and X═H, F, Cl, Br, I, or CH 3 or a compound of the formula
wherein: Y═H or OH and X═H, F, Cl, Br, or I, or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, and thereby treating the tumor.
13. The method of claim 12 , wherein the compound is
wherein: Y═H or OH and X═H, F, Cl, Br, I, or CH 3
wherein: Y═H or OH and X═H, F, Cl, Br, or I, or a pharmaceutically acceptable salt thereof.
14. The method of claim 12 , wherein the compound or salt has the formula:
15. The method of claim 12 , wherein the compound or salt has the formula:
16. The method of claim 12 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
17. The method of claim 12 , said composition further comprising a pharmaceutically acceptable carrier or diluent.
18. The method of claim 12 , said tumor selected from tumors of the ovary, tumors of the breast, cervical tumors, tumors of the prostate, tumors of the liver, lung tumors, kidney tumors, colon tumors, pancreatic tumors, brain tumors, stomach tumors and melanoma.